文献速递新发突发、热带与寄生虫病

印度东部pfkelch13新基因多态性与青蒿素耐药相关

Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该研究纳入226例无并发症恶性疟患者,评估ASSP方案42天疗效。12%分离株清除半衰期>5小时,治愈率降至84.1%,15.9%治疗失败。10.6%患者携带pfkelch13多态性且清除半衰期延长,其中15例符合WHO青蒿素耐药标准,13例为G625R、2例为R539T突变。

要点

  • 印度东部出现青蒿素耐药恶性疟分离株,ASSP治愈率降至84.1%。
  • 15例分离株符合WHO青蒿素耐药标准,携带pfkelch13 G625R或R539T突变。
  • 耐药株环状体存活率中位数12.2%,显著高于治愈患者0.9%。

核心结论

  • 印度东部发现青蒿素耐药恶性疟分离株,伴随新突变和联合治疗失败增加,需紧急加强疟疾控制。

研究设计与样本

  • 前瞻性研究纳入226例无并发症恶性疟原虫感染患者,均完成ASSP联合治疗42天随访,时间2014年4月至2016年1月。

主要发现

  • 12%分离株清除半衰期>5小时,ASSP治愈率约84.1%,治疗失败率15.9%(早期7.9%,晚期7.9%)。
  • 24例(10.6%)患者清除半衰期>5小时且携带pfkelch13 441密码子后多态性,其中15例(6.6%)72小时未清除寄生虫。
  • 15例耐药株环状体存活率中位数12.2%(95%CI 10.9-13.8),治愈患者为0.9%(95%CI 0.09-1.07)。
  • 15例中13例为pfkelch13 G625R多态性,2例为R539T多态性,符合WHO青蒿素耐药标准。

关键数值与推荐

  • WHO青蒿素耐药判定标准:寄生虫清除半衰期>5小时且72小时未清除,本研究中15例分离株符合。

临床怎么用

  • 在印度东部及类似地区应监测pfkelch13多态性和寄生虫清除半衰期,警惕ASSP疗效下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Artesunate-sulfadoxine-pyrimethamine (ASSP) is the frontline artemisinin combination therapy (ACT) in India. Random, irrational, subtherapeutic artemisinin doses and self-medication with ACT along with predominance of sulfadoxine-pyrimethamine resistance parasite invoked a strong possibility of emerging artemisinin-resistant malaria parasites. METHODS: This study involved 226 patients with uncomplicated Plasmodium falciparum infection who had successfully completed the 42 days follow-up after ASSP combination therapy from April 2014 to January 2016. We assessed the ASSP treatment efficacy by evaluating parasite clearance half-life, pfkelch13, and other (pfdhfr, pfdhps, pfmdr1, pfcrt) gene mutations and survival of parasites as detected by an ex vivo ring-stage survival assay (RSA). FINDINGS: Slow-clearing infections with longer parasite clearance half-lives (>5 hours) were observed in 12% isolates. Cure rate after ASSP treatment was declining to about 84.1%. ASSP failure was recorded in 15.9% (early treatment failure, 7.9%; late treatment failure, 7.9%) of isolates. In sum, 24 patients (10.6%) had parasite clearance half-lives greater than 5 hours with pfkelch13 polymorphism after 441 codon; in 15 of those patients (6.6%), parasites had not cleared by 72 hours after initiation of therapy. Median ex vivo ring-stage survival rate of these isolates was very high (12.2%; 95% confidence interval [CI], 10.9-13.8) from that of cured patients (0.9%; 95% CI, 0.09-1.07). Of these 15 patients, 13 patients had pfkelch13 G625R polymorphism, whereas 2 patients contained R539T polymorphism. As per the World Health Organization guideline, these 15 isolates were true artemisinin-resistant isolates. INTERPRETATION: Identification of artemisinin-resistant isolates in India together with new mutations and increasing combination therapy failures blow alarms for urgent malaria control.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Das S, Manna S, Saha B, et al. Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India. Clin Infect Dis. 2019. PMID: 30535043. doi:10.1093/cid/ciy1038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。